Lupin Pharmaceuticals Inc., a subsidiary of pharma major, Lupin Ltd., has received final approval for its lamivudine and zidovudine tablets, 150 mg/300 mg. from the United States Food and Drugs Administration (FDA).
Lupin has already commenced shipping the product. Lupin's lamivudine and zidovudine tablets are AB-rated generic equivalent of ViiV Healthcare's Combivir tablets USP 150/300mg had annual sales of approximately US$ 275 million for 12 months ending December 2011 (IMS Health Data).
Lamivudine zidovudine is a combination of two nucleoside analogue reverse transcriptase inhibitors and is indicated in combination with Oilier an ti retro vital agents for the treatment of HIV-1 infection.